throbber
Filed on behalf of Patent Owner Genentech, Inc. by:
`
`
`David L. Cavanaugh (Reg. No. 36,476)
`Robert J. Gunther, Jr. (Pro Hac Vice)
`Lisa J. Pirozzolo (Pro Hac Vice)
`Kevin S. Prussia (Pro Hac Vice)
`Andrew J. Danford (Pro Hac Vice)
`WILMER CUTLER PICKERING
` HALE AND DORR LLP
`1875 Pennsylvania Ave., NW
`Washington, DC 20006
`
`Adam R. Brausa (Reg. No.
`60,287)
`Daralyn J. Durie (Pro Hac
`Vice)
`DURIE TANGRI LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________________________
`
`CELLTRION, INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner.
`____________________________________________
`
`Case IPR2017-01374
`Patent 6,407,213
`____________________________________________
`
`PATENT OWNER’S RENEWED MOTION TO SEAL
`
`

`

`
`
`
`IPR2017-01374
`
` Patent Owner’s Renewed Motion to Seal
`
`
`STATEMENT OF PRECISE RELIEF REQUESTED
`
`Pursuant to 37 C.F.R. §§ 42.14 and 42.54, and the Board’s Final Written
`
`Decision, Paper 85, Patent Owner Genentech, Inc. respectfully submits this
`
`renewed motion to seal certain parts of Exhibits 2001 (Laboratory Notebook 10098
`
`(Leonard Presta)), 2002 (Laboratory Notebook 10823 (Leonard Presta)), 2005
`
`(Laboratory Notebook 10840 (John Brady)), and 2006 (Laboratory Notebook
`
`11162 (John Brady)) that describe confidential research unrelated to the issues in
`
`this proceeding. Patent Owner files concurrently with this motion redacted
`
`versions of these exhibits.
`
`As discussed below, Patent Owner is only seeking to seal certain portions of
`
`Exhibits 2001, 2002, 2005, and 2006 that are not relevant to any issue in this
`
`proceeding and that were not relied upon in the Final Written Decision. Given the
`
`public disclosure of Genentech’s work humanizing the 4D5 antibody at the oral
`
`hearing and the Board’s reliance on that work in its Final Written Decision, see
`
`Paper 85 at 17-25, Patent Owner does not request the sealing of the Final Written
`
`Decision, any paper previously filed in this proceeding, or any other exhibit
`
`submitted in this proceeding.
`
`REASONS FOR RELIEF REQUESTED
`
`Although “the default rule is that all papers filed in an inter partes review
`
`are open and available for access by the public,” a party may file a motion with the
`1
`
`
`
`

`

`
`
`
`IPR2017-01374
`
` Patent Owner’s Renewed Motion to Seal
`
`Board to seal confidential information that is protected from disclosure. Garmin v.
`
`Cuozzo, IPR2012-00001, Paper No. 36. “The standard for granting a motion to
`
`seal is ‘for good cause.’” Id. (quoting 37 C.F.R § 42.54); see Argentum Pharms.
`
`LLC v. Alcon Research, Ltd., IPR2017-01053, Paper 27 at 3-4 (Jan. 19, 2018)
`
`(informative). The Office Patent Trial Practice Guide, 77 Fed. Reg. 48756, 48760
`
`(Aug. 14, 2012), states that the “rules identify confidential information in a manner
`
`consistent with Federal Rule of Civil Procedure (“FRCP”) 26(c)(1)(G), which
`
`provides for protective orders for trade secret or other confidential research,
`
`development, or commercial information.”
`
`The parties have conferred and agreed to the provisions of the Modified
`
`Default Standing Protective Order set forth in Exhibit 2030, and have stipulated to
`
`be bound to the terms set forth therein. Exhibit 2031 shows the proposed
`
`modifications from the Default Standing Protective Order, to which the parties
`
`have stipulated, in redline. The Modified Default Standing Protective Order
`
`provides:
`
`Where confidentiality is alleged as to some but not all of the
`
`information submitted to the Board, the submitting party shall file
`
`confidential and non-confidential versions of its submission, together
`
`with a Motion to Seal the confidential version setting forth the reasons
`
`why the information redacted from the non-confidential version is
`2
`
`
`
`

`

`
`
`
`confidential and should not be made available to the public. The
`
`IPR2017-01374
`
` Patent Owner’s Renewed Motion to Seal
`
`
`nonconfidential version of the submission shall clearly indicate the
`
`locations of information that has been redacted. The confidential
`
`version of the submission shall be filed under seal. The redacted
`
`information shall remain under seal unless, upon motion of a party
`
`and after a hearing on the issue, or sua sponte, the Board determines
`
`that some or all of the redacted information does not qualify for
`
`confidential treatment.
`
`(Ex. 2030, Modified Default Standing Protective Order and Patent Owner’s
`
`Certification of Agreement to Terms, at 3-4.)
`
`Exhibits 2001 and 2002 are laboratory notebooks authored by Dr. Leonard
`
`Presta, who is an inventor of U.S. Patent No. 6,407,213 (“the ’213 patent”).
`
`Exhibits 2001 and 2002 describe Dr. Presta’s work humanizing the 4D5 antibody,
`
`which is described in the ’213 patent. But Exhibits 2001 and 2002 also describe
`
`Dr. Presta’s confidential research on other projects that are unrelated to the issues
`
`in this proceeding and that occurred after his work humanizing the 4D5 antibody.
`
`Patent Owner requests to seal the description of these unrelated experiments in the
`
`table of contents on page 5 of Exhibit 2001, as well as the detailed experimental
`
`description on pages 42-90 of Exhibit 2001 and pages 40-68 of Exhibit 2002.
`
`
`
`3
`
`

`

`
`
`
`Exhibits 2005 and 2006 are laboratory notebooks authored by Mr. John
`
`IPR2017-01374
`
` Patent Owner’s Renewed Motion to Seal
`
`
`Ridgeway Brady, which corroborate the inventors’ work relating to the ’213
`
`patent. Patent Owner does not request to seal any portion of Mr. Brady’s
`
`notebooks cited or discussed in these proceedings. However, there are certain
`
`experiments in the beginning of Exhibits 2005 and 2006 that do not relate to
`
`humanized 4D5 antibodies and therefore are not relevant to the issue of
`
`corroboration or any other issue in these proceedings. Patent Owner requests to
`
`seal the details of this confidential research that does not involve humanized 4D5
`
`antibodies on pages 13-72 of Exhibit 2005 and pages 13-46 of Exhibit 2006.
`
`The material that Patent Owner requests to seal is maintained confidentially
`
`at Genentech, and the public disclosure of such confidential research and
`
`development materials would place Genentech at a competitive disadvantage.
`
`Patent Owner is submitting concurrently herewith redacted versions of Exhibits
`
`2001, 2002, 2005, and 2006, and attests that the materials sought to be protected is
`
`not directly or indirectly relied on in the Board’s Final Written Decision. Rather,
`
`the only information that Patent Owner is seeking to redact in Exhibits 2001, 2002,
`
`2005, and 2006 are the details of confidential experiments unrelated to the issues in
`
`
`
`4
`
`

`

`
`
`
`this proceeding.1 There is therefore good cause for sealing these confidential
`
`IPR2017-01374
`
` Patent Owner’s Renewed Motion to Seal
`
`
`research materials, and no countervailing public interest that would warrant
`
`unsealing the portions of these exhibits that are unrelated to the issues in this
`
`proceeding. Indeed, in related IPR2017-01373 and IPR2017-01489, the Board
`
`granted Patent Owner’s motion to seal these materials where, as here, the material
`
`sought to be sealed was not relied upon the Final Written Decision. See IPR2017-
`
`01373, Paper 84, at 54-55 (sealing, inter alia, Exhibits 2001, 2002, 2005, and
`
`2006); IPR2017-01489, Paper 86, at 53 (same).
`
`
`1
`The Board referred to the dates and signatures on pages 43-63, 65, 68-71,
`
`73, 74, 77-84, and 90 of Exhibit 2001 and pages 40-43, 46, 51, 59-61, and 64-68 of
`
`Exhibit 2002 in related IPR2017-01488 to refute “Petitioner’s suggestion that [the
`
`notebooks] are substantially unsigned and undated.” See IPR2017-01488, Paper
`
`87 at 25 n.14. The Board did not rely upon or discuss the experimental details
`
`described on those pages, which do not relate to the inventors’ work humanizing
`
`the 4D5 antibody at issue in this proceeding. Patent Owner does not request that
`
`the dates and signatures referred to in the Final Written Decision in IPR2017-
`
`01488 be sealed; Patent Owner only requests to seal the details of the unrelated
`
`research described on those pages.
`
`
`
`5
`
`

`

`
`
`
`Patent Owner therefore respectfully requests that the Board grant this
`
`IPR2017-01374
`
` Patent Owner’s Renewed Motion to Seal
`
`
`renewed motion to seal portions of Exhibits 2001, 2002, 2005, and 2006 as
`
`reflected in Patent Owner’s redacted versions of these exhibits submitted herewith.
`
`
`
`Date: December 13, 2018
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/David L. Cavanaugh/
`David L. Cavanaugh
`Registration No. 36,476
`
`Counsel for Patent Owner
`
`
`
`
`
`
`
`WILMER CUTLER PICKERING HALE AND DORR LLP
`1875 PENNSYLVANIA AVENUE NW
`WASHINGTON, DC 20006
`TEL: 202-663-6000
`FAX: 202-663-6363
`EMAIL: david.cavanaugh@wilmerhale.com
`
`
`
`6
`
`

`

`
`
`
`IPR2017-01374
`Patent Owner’s Updated Exhibit List
`
`
`IPR2017-01374
`Patent Owner’s Updated Exhibit List
`
`Patent Owner’s
`Exhibit Number
`2001
`
`
`2002
`
`2003
`2004
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`2013
`2014
`2015
`
`2016
`2017
`2018
`2019
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit Name
`
`Genentech, Inc. Laboratory Notebook No. 10098 (Leonard
`Presta)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 10823 (Leonard
`Presta)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 11268 (Paul Carter)
`Genentech, Inc. Laboratory Notebook No. 11643 (Paul Carter)
`Genentech, Inc. Laboratory Notebook No. 10840 (John Brady)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 11162 (John Brady)
`PROTECTIVE ORDER MATERIAL
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11008
`(Ann Rowland)
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11297
`(Tim Hotaling)
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11568
`(Monique Carver)
`Genentech, Inc. Interoffice Memorandum from Paul Carter to
`Leonard Presta and Dennis Henner
`Genentech, Inc. Interoffice Memorandum from Paul Carter to
`Leonard Presta
`Genentech, Inc. Synthetic DNA Requests
`Genentech, Inc. Synthetic DNA Requests
`Genentech, Inc. Protein Engineering of 4D5 Status Report
`Genentech, Inc. Interoffice Memorandum re: RCC Minutes and
`Recommendations
`Declaration of Dr. Leonard G. Presta
`Declaration of Dr. Paul J. Carter
`Declaration of John Ridgway Brady
`Declaration of Irene Loeffler
`
`7
`
`
`
`
`
`
`
`
`
`

`

`Patent Owner’s
`Exhibit Number
`2020
`
`
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`2028
`
`2029
`2030
`
`2031
`2032
`
`2033
`
`2034
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-01374
`Patent Owner’s Updated Exhibit List
`
`
`Exhibit Name
`
`Paul Carter, et al., Humanization of the Anti-p185 Antibody for
`Human Cancer Therapy, 89 PROC. NATL. ACAD. SCI. 4285-
`4289 (1992)
`Leonard Presta, et al., Humanization of an Anti-Vascular
`Endothelial Growth Factor Monoclonal Antibody for the
`Therapy of Solid Tumors and Other Disorders, 57 CANCER
`RESEARCH 4593-4599 (1997)
`Marianne Brüggerman, et al., The Immunogenicity of Chimeric
`Antibodies, 170 J. EXP. MED. 2153-2157 (1989)
`Jatinderpal Kalsi, et al., Structure-function Analysis and the
`Molecular Origins of Anti-DNA Antibodies in Systemic Lupus
`Erythematosus, EXPERT REVIEWS IN MOLECULAR MEDICINE 1-
`28 (1999)
`Scott Gorman, et al., Reshaping a Therapeutic CD4 Antibody,
`88 PROC. NATL. ACAD. SCI. 4181-4185 (1991)
`John Isaacs, et al., Humanised Monoclonal Antibody Therapy
`for Rheumatoid Arthritis, 340 THE LANCET 748-752 (1992)
`Elvin Kabat, et al., Sequences of Proteins of Immunological
`Interest 1-23 (4th ed. 1987)
`Anna Tramontano, et al., Framework Residue 71 Is a Major
`Determinant of the Position and Conformation of the Second
`Hypervariable Region in the VH Domains of Immunoglobulins,
`215 J. MOL. BIOL. 175-182 (1990)
`H.M. Shepard, et al., Herceptin, in THERAPEUTIC ANTIBODIES.
`HANDBOOK OF EXPERIMENTAL PHARMACOLOGY 183-219 (Y.
`Chernajovsky & A. Nissim, eds. 2008)
`Excerpt from Roche Finance Report 2016
`Modified Default Standing Protective Order and Patent
`Owner’s Certification of Agreement to Terms
`Modified Default Standing Protective Order – Redline
`Declaration of Robert J. Gunther, Jr. in support of Motion for
`Admission Pro Hac Vice
`Declaration of Daralyn J. Durie in support of Motion for
`Admission Pro Hac Vice
`Declaration of Lisa J. Pirozzolo in support of Motion for
`Admission Pro Hac Vice
`
`8
`
`

`

`Patent Owner’s
`Exhibit Number
`2035
`
`
`2036
`
`2037
`
`2038
`2039
`
`2040
`
`2041
`2042
`2043
`2044
`
`2045
`
`2046
`2047
`2048
`2049
`2050
`2051
`2052
`2053
`
`2054
`
`2055
`
`2056
`2057
`2058
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-01374
`Patent Owner’s Updated Exhibit List
`
`
`Exhibit Name
`
`Declaration of Kevin S. Prussia in support of Motion for
`Admission Pro Hac Vice
`Declaration of Andrew J. Danford in support of Motion for
`Admission Pro Hac Vice
`File History for U.S. Patent Application No. 07/715,272
`Immunoglobulin Variants (filed June 14, 1991).
`Reserved
`Deposition Transcript of Lutz Riechmann, Celltrion, Inc. v.
`Genentech, Inc. (PTAB), Feb. 14, 2018
`Deposition Transcript of Robert Leonard, Celltrion, Inc. v.
`Genentech, Inc. (PTAB), Feb. 16, 2018
`Expert Declaration of Dr. Ian A. Wilson
`U.S. Patent No. 7,375,193
`U.S. Patent No. 7,560,111
`Leonard Presta, et al., Humanization of an Antibody Directed
`Against IgE, 151 J. IMMUNOLOGY 2623-2632 (1993)
`A. Bondi, van de Waals Volumes and Radii, 68 J. PHYSICAL
`CHEMISTRY 441-451 (1964)
`Reserved
`Reserved
`Reserved
`Reserved
`Reserved
`Reserved
`Reserved
`Ole Brekke, et al., Therapeutic Antibodies for Human Diseases
`at the Dawn of the Twenty-First Century, 2 NATURE REVIEWS |
`DRUG DISCOVERY 52- 62 (2003)
`Thomas A. Waldmann, Monoclonal Antibodies in Diagnosis
`and Therapy, 252 SCIENCE 1657-1662 (1991)
`Greg Winter, et al., Antibody-Based Therapy: Humanized
`Antibodies, 14 TIPS 139-143 (1993)
`Reserved
`Reserved
`Reserved
`
`9
`
`

`

`Patent Owner’s
`Exhibit Number
`2059
`
`
`2060
`
`2061
`
`2062
`
`2063
`
`2064
`
`2065
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-01374
`Patent Owner’s Updated Exhibit List
`
`
`Exhibit Name
`
`Gert Riethmüller, et al., Monoclonal Antibodies in the
`Detection and Therapy of Micrometastic Epthelial Cancers, 4
`CURRENT OP. IMMUNOLOGY 647-655 (1992)
`Gert Riethmüller, et al., Monoclonal Antibodies in Cancer
`Therapy, 5 CURRENT OP. IMMUNOLOGY 732-739 (1993)
`Mark D. Pegram, et al., Phase II Study of Receptor-Enhanced
`Chemosensitivity Using Recombinant Humanized Anti-
`pl85HER2/neu Monoclonal Antibody Plus Cisplatin in Patients
`with HER2/neu-Overexpressing Metastatic Breast Cancer
`Refractory to Chemotherapy Treatment, 16 J. CLINICAL
`ONCOLOGY 2659-2671 (1998)
`Redline of IPR2016-01694 Expert Declaration of Dr. Eduardo
`A. Padlan in Support of Petition for Inter Partes Review of
`Patent No. 6,407,213 and IPR2017-01373 Expert Declaration
`of Lutz Riechmann, Ph.D., in Support of Petition for Inter
`Partes Review of Patent No. 6,407,213
`Corrected Exhibit P of Expert Declaration of Lutz Riechmann,
`Ph.D., in Support of Petition for Inter Partes Review of Patent
`No. 6,407,213
`Deposition Transcript of Lutz Riechmann, Celltrion, Inc. v.
`Genentech, Inc. (PTAB), June 19, 2018
`Transcript of Conference Call, Celltrion, Inc. v. Genentech,
`Inc., June 18, 2018
`
`
`
`
`10
`
`
`
`
`
`
`

`

`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that, on December 13, 2018, I caused a true and correct copy of the
`
`following materials:
`
` Patent Owner’s Renewed Motion to Seal
`
` Patent Owner’s Updated Exhibit List
`
` Exhibits 2001, 2002, 2005, and 2006
`
`to be served via electronic mail on the following attorneys of record:
`
`Cynthia Lambert Hardman
`GOODWIN PROCTER LLP
`chardman@goodwinlaw.com
`620 Eighth Avenue New York, NY 10018
`
`Robert V. Cerwinski
`GOODWIN PROCTER LLP
`rcerwinski@goodwinlaw.com
`620 Eighth Avenue New York, NY 10018
`
`Elizabeth Holland
`GOODWIN PROCTER LLP
`eholland@goodwinlaw.com
`620 Eighth Avenue New York, NY 10018
`
`Linnea P. Cipriano
`GOODWIN PROCTER LLP
`lcipriano@goodwinlaw.com
`620 Eighth Avenue New York, NY 10018
`
`Sarah J. Fischer
`GOODWIN PROCTER LLP
`sfischer@goodwinlaw.com
`100 Northern Avenue, Boston, MA 02110
`11
`
`
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/ Jennifer Graber/
`Jennifer Graber
`
`
`WILMER CUTLER PICKERING HALE AND DORR LLP
`7 WORLD TRADE CENTER
`250 GREENWICH STREET
`NEW YORK, NY 10007
`TEL: 212-295-6446
`FAX: 212-230-8888
`EMAIL: jennifer.graber@wilmerhale.com
`
`
`
`12
`
`
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket